|Bid||1.1700 x 800|
|Ask||1.1800 x 4000|
|Day's Range||1.0800 - 1.2000|
|52 Week Range||1.0200 - 3.8900|
|Beta (5Y Monthly)||0.98|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 09, 2021 - Aug 13, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.25|
Before we start, let me remind you that today's call will include forward-looking statements based on current expectations, including statements concerning our financial outlook for the future, management's expectations for our future financial and operational performance, our business strategy, our assessment of the combined hormonal contraceptive market and the potential market share for Twirla, among other statements regarding our plans, prospects, and expectations. Such statements represent our judgments as of today, are not promises or guarantees, and may involve risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements.
Agile Therapeutics (AGRX) delivered earnings and revenue surprises of 4.76% and -18.28%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Total Prescriptions (TRx) Grew 171% in Second Quarter Prescribers, New Prescriptions and Refill Rates Continue to Grow in Second Quarter Company Continues to Progress on Expanding Access to Twirla Management to Host Conference Call Today, Monday, July 26, 2021 at 4:30 p.m. EDT PRINCETON, N.J., July 26, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three months ended June 30, 2021 and provided a corporate u